U.S. Insurance Stock News

If you are wondering whether SPS Commerce shares are now priced attractively or still look expensive, you are not alone. This review is aimed squarely at that question. The stock most recently closed at US$58.41, with returns of 7.7% over the past week, a 34.6% decline over 30 days, a 33.6% decline year to date, and a 55.8% decline over 1 year. The 3 year and 5 year returns stand at 61.2% and 41.1% declines respectively. Recent coverage around SPS Commerce has focused on keeping investors...

Veracyte (VCYT) has drawn attention after recent share price moves, with the stock showing mixed returns across different time frames, including declines over the past month and past 3 months alongside a positive 1 year total return. See our latest analysis for Veracyte. At a share price of US$36.01, Veracyte’s recent performance reflects fading short term momentum, with a 30 day share price return of 5.44% and a 90 day share price return of a 21.99% decline, set against a 1 year total...

In late February 2026, Virtu Financial reported Q4 2025 results showing its highest quarterly adjusted net income since early 2021, supported by elevated market volatility and strong trading volumes across both Market Making and Execution Services. An interesting angle for investors is Virtu’s plan to channel this momentum into higher trading capital, upgraded infrastructure, and moves into emerging areas such as prediction markets and crypto. We’ll now explore how this stronger quarter,...

Hormel Foods stock snapshot Hormel Foods (HRL) shares trade around US$24.82, with the stock roughly flat over the past month and showing a gain in the past 3 months, set against weaker 1 year and multi year returns. See our latest analysis for Hormel Foods. The recent 1 day share price decline of 3.05% sits against a 90 day share price return of 7.49%. The 1 year total shareholder return of 12% and 5 year total shareholder return of 39.51% highlight how sentiment has weakened over time...

In February 2026, UiPath unveiled new agentic AI solutions for healthcare at the ViVE 2026 conference, targeting medical records summarization, claim denial prevention and resolution, and prior authorization, developed in collaboration with Genzeon to address data fragmentation and revenue cycle management challenges for providers and payers. By pairing agentic automation with healthcare-domain partners like Genzeon, UiPath is moving beyond generic RPA into deeply specialized,...

Zenas BioPharma has recently been highlighted for moving from a pre-revenue stage toward commercialization of its lead antibody therapy obexelimab, targeting IgG4-Related Disease, an area with no approved treatments. An interesting aspect of this story is Zenas’ reported cash position of about US$270,000,000 entering 2026, which supports its plans to expand a pipeline focused on B‑cell‑mediated autoimmune diseases while advancing obexelimab toward market. Against this backdrop, we’ll examine...

IREN (NasdaqGS:IREN) is back in focus after securing a US$9.7b, five year AI cloud services contract with Microsoft, a shift that places its high performance computing and AI infrastructure front and center for investors. See our latest analysis for IREN. Despite the Microsoft contract putting IREN firmly on the AI map, the 30 day share price return of 22.98% decline and year to date softness contrast with a very large 1 year total shareholder return. This suggests powerful but volatile...

If you are looking at Fluor and wondering whether the current share price gives you good value, you are not alone. This article focuses squarely on what you might be paying for compared to what you are getting. After closing at US$50.91, the stock has seen a 1.4% decline over the last 7 days, a 10.2% gain over 30 days, a 22.1% return year to date, and a 37.9% return over the past year, which may change how investors think about both upside and risk. Recent attention on Fluor has been driven...

Advance Auto Parts (AAP) is back on many investors’ screens after its share price returned 37% year to date, even though 3 year and 5 year total returns remain deeply negative. See our latest analysis for Advance Auto Parts. That 36.98% year to date share price return and 53.92% 1 year total shareholder return suggest improving sentiment around Advance Auto Parts, even though the 3 and 5 year total shareholder returns remain sharply negative. If this rebound has you thinking about what else...

If you are wondering whether U.S. Physical Therapy shares still offer fair value at around US$83, you are not alone, many investors are asking the same question. The stock has had a mixed run, with a 0.6% decline over the last week, a 1.0% decline over the last month, a 5.3% gain year to date and a 6.7% return over the past year, while the 3 year and 5 year returns sit at 8.0% and 20.6% declines respectively. Recent news coverage has mainly focused on U.S. Physical Therapy as an established...

Earnings beat, guidance shock and what changed for MongoDB (MDB) MongoDB (MDB) topped expectations with its latest quarterly earnings and revenue, yet cautious guidance for the next quarter and fiscal year, leadership changes and insider selling all combined to hit the stock hard. See our latest analysis for MongoDB. At a share price of $325.01, MongoDB has seen a 6.43% 7 day share price gain but a 12.47% 30 day and 18.68% year to date share price decline. Its 1 year total shareholder return...

Exzeo Group has entered into a new partnership with Tokio Marine Highland to distribute TMH2O residential flood insurance. The collaboration expands Exzeo’s property insurance offerings and supports its ambitions as a multi-line, technology driven platform. For investors tracking NYSE:XZO, this announcement comes as the stock trades at $16.1, with a 3.7% gain over the past week and a 20.8% decline over the past month. Year to date, shares show a 29.3% decline, so this move may stand out as...

If you are wondering whether First Solar's current share price reflects its true worth, this article will walk through how that value stacks up against a range of valuation checks. The stock last closed at US$199.86, with a 17.5% decline over the past 7 days and an 11.4% decline over the past 30 days, although the 1 year return sits at 56.6% and the 5 year return at 179.7%. These moves come as First Solar continues to sit in the spotlight of the wider solar and semiconductor industry, with...

Key recent performance drivers for Valaris With no single headline event setting the tone, Valaris (VAL) has still drawn attention after a recent share price move. This has left investors weighing how its fundamentals line up with the current valuation. See our latest analysis for Valaris. After a sharp 60.40% 1 month share price return and 77.56% year to date share price return to US$92.60, recent 1 day and 7 day pullbacks suggest some momentum may be cooling, even as the 181.89% 1 year...

Paramount Skydance agreed to acquire Warner Bros. Discovery (NasdaqGS:WBD) in an all stock and cash transaction valued at about $110b. The deal, which follows a bidding contest in which Netflix dropped out, is expected to close in Q3 2026, subject to regulatory and shareholder approval. The combined group plans to bring together HBO Max and Paramount+, along with major film and TV franchises under one media company. Warner Bros. Discovery enters this deal with its shares at $28.5 and a 1...

Ethereum rally puts Sharplink’s treasury model in focus Sharplink (SBET) is back on watch after Ethereum’s latest rally, with the company’s large ETH treasury and staking driven business model pulling the stock closely in line with crypto market moves. See our latest analysis for Sharplink. At a share price of US$7.39, Sharplink’s stock has recently swung higher with a 1-day share price return of 8.36% and a 7-day share price return of 13.87%. These short bursts follow a weaker patch marked...

Vistra overview and recent share performance Vistra (VST) has recently drawn attention after a period of mixed share performance, with the stock showing a small monthly gain alongside a modest decline over the past 3 months and the past week. For context, the company last closed at $165.99, with a year-to-date return close to flat and a 1-year total return above 30%. Over longer periods, total returns over 3 and 5 years have been very large, reflecting a multi-year move that existing...

Event overview and recent share performance Charles River Laboratories International (CRL) has drawn investor attention after recent share price moves, with the stock flat over the past day, up about 9% over the past week, but showing a 15% decline over the past month. Over the past 3 months, Charles River has posted a small positive total return, while year to date the stock is down about 12%. Over the past year, it has delivered roughly 9% total return, set against weaker 3 year and 5 year...

The Morning Bull - US Market Morning Update Tuesday, Mar, 3 2026 US stock futures are pointing lower this morning, with E mini S&P 500 contracts down about 1.5%, the Nasdaq 100 futures off nearly 2% and small cap Russell 2000 futures lower by about 2.6%. The pressure comes as the US 10 year Treasury yield holds near 4.04%, which keeps borrowing costs elevated for households and businesses, and as global government bond yields in the UK and Europe climb on renewed inflation worries tied to...

ONE Gas (OGS) has moved into the spotlight after announcing a US$225 million follow on equity offering and a new US$41.2 million shelf registration, shortly after releasing full year 2025 earnings and leadership changes. See our latest analysis for ONE Gas. Despite the recent equity offering and shelf registration, ONE Gas’ share price has a 30 day share price return of 9.82% and a year to date share price return of 12.85%, while the 1 year total shareholder return of 18.86% and 5 year total...

Haemonetics (HAE) is back in focus after receiving FDA 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS, a next-generation platform designed to tailor plasma collection volumes to individual donors. See our latest analysis for Haemonetics. Despite the FDA clearance and recent conference appearance, Haemonetics’ share price, last closing at $63.88, shows mixed momentum. The stock has a 4.23% 7 day share price return, but a 20.13% decline year to date and a 20.93%...

If you are wondering whether Matador Resources at around US$54.12 is priced attractively or already baking in a lot of optimism, you are not alone. The stock has returned 5.8% over the last 7 days, 19.6% over the last 30 days, 24.8% year to date, 16.9% over 1 year, 0.7% over 3 years and 131.2% over 5 years, which naturally raises questions about what is already reflected in the price. Recent attention on Matador Resources has focused on its position in the US energy sector and how investors...

If you are wondering whether Frontdoor's share price still reflects good value after a strong run, this article walks through what the current market price might be implying about the business. Frontdoor's stock closed at US$67.46, with returns of 22.7% over the last 7 days, 14.1% over 30 days, 18.3% year to date, 65.9% over 1 year and 135.1% over 3 years, while the 5 year return sits at 24.2%. Recent coverage has focused on Frontdoor's position in home service plans and how its offerings...

Former Goldman Sachs (NYSE:GS) CEO Lloyd Blankfein has warned of potential systemic risks tied to the rapid expansion of private credit and shadow banking. His comments focus on hidden leverage and illiquid assets that may sit outside traditional bank balance sheets. The warning comes as investors pay closer attention to how credit risk is distributed across banks, non bank lenders, and the broader financial system. Goldman Sachs is a global investment bank and financial services firm...